Theres a lot scientists dont yet know about GLP-1s, including longrun effects on the brain (positive and negative)
Its older approval and more modest efficacy profile mean most new prescriptions now favor semaglutide or tirzepatide when access and insurance permit
So when managing it becomes part of your
Total glutathione increased in most compartments of the vtc2-1 mutant, but particularly in the chloroplasts and nuclei (Heyneke et al
By extrapolation from the established profiles of approved GLP-1 receptor agonists including semaglutide (Wegovy SmPC, MHRA/EMC) and tirzepatide (Mounjaro SmPC, MHRA/EMC) clinicians should anticipate the need to review and potentially reduce antihypertensive doses as significant weight loss occurs, in line with BNF and NICE guidance principles
They may need to review your semaglutide dosage, evaluate for interactions with other medications you are taking, or consider alternative treatments